ArticleArchives of toxicology2026
6PPD metabolic activation by CYP3A initiates cytotoxicity in mouse primary hepatocytes.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-(1,3-Dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD) is a widely used rubber antioxidant and an emerging environmental pollutant, yet its hepatotoxic potential and the underlying role of metabolic activation remain poorly understood. Here, we integrated metabolite profiling, liver microsomal incubations, chemical oxidation synthesis, and mouse primary hepatocytes and animal exposure to examine the metabolic and toxicological outcomes of 6PPD. A total of 54 metabolites were identified in mice, including phase I oxidation products and phase II conjugates. Importantly, the reactive metabolite p-benzoquinone diimide (6PPD-QDI) was detected and shown to form conjugates with biological thiols. In microsomal incubations containing glutathione (GSH), N-acetylcysteine (NAC), or cysteine conjugates, 6PPD produced the corresponding conjugates, supporting the generation of 6PPD-QDI. The conjugate formation was NADPH-dependent and substantially suppressed by the CYP3A inhibitor ketoconazole, indicating that CYP3A mediates the bioactivation of 6PPD. In vivo, identical GSH and NAC conjugates were detected in bile and urine of exposed mice, and hepatic proteins contained dose-dependent protein adduction at cysteine residues. In primary hepatocytes, 6PPD induced concentration- and time-dependent cytotoxicity associated with GSH depletion and protein adduction, which was mitigated by CYP3A inhibition or thiol supplementation. Notably, CYP3A4-overexpressing HepG2 cells exhibited enhanced susceptibility to cytotoxicity and protein adduction compared to wild-type cells.
Indexed as
Identifiers
42159744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.